`__________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`__________________
`
`NALOX-1 PHARMACEUTICALS, LLC,
`Petitioner,
`
`v.
`
`OPIANT PHARMACEUTICALS, INC.,
`Patent Owner.
`__________________
`
`Case No. IPR2019-00694
`U.S. Patent No. 9,629,965
`__________________
`
`DECLARATION OF ANA C. REYES IN SUPPORT OF MOTION FOR
`PRO HAC VICE ADMISSION PURSUANT TO 37 C.F.R. § 42.10(c)
`
`Opiant Exhibit 2038
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00694
`Page 1
`
`
`
`I, Ana C. Reyes, am more than twenty-one years of age, am competent to
`
`present this declaration, have personal knowledge of the facts set forth herein, and
`
`hereby declare as follows:
`
`1.
`
`This declaration is given in support of Patent Owner Adapt Pharma
`
`Operations Limited’s Motion for Pro Hac Vice Admission of Ana C. Reyes.
`
`2.
`
`I am a partner at Williams & Connolly LLP, 725 12th St., NW,
`
`Washington, DC 20005. I have more than eighteen years of litigation experience.
`
`3.
`
`I am a member in good standing of the bars of New York, the District
`
`of Columbia, and Kentucky.
`
`4.
`
`I have never been suspended or disbarred from practice before any
`
`court or administrative body.
`
`5.
`
`No court or administrative body has ever denied my application for
`
`admission to practice before it.
`
`6.
`
`No court or administrative body has ever imposed sanctions or
`
`contempt citations on me.
`
`7.
`
`I have read and will comply with the Office Patent Trial Practice
`
`Guide and the Board’s Rules of Practice for Trials set forth in part 42 of 37 C.F.R.
`
`8.
`
`I understand that I will be subject to the USPTO Code of Professional
`
`Responsibility set forth in 37 C.F.R. §§ 11.101 et seq. and will be subject to
`
`disciplinary jurisdiction under 37 C.F.R. § 11.19(a).
`
`Opiant Exhibit 2038
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00694
`Page 2
`
`
`
`9.
`
`I am concurrently seeking pro hac vice admission in the Petitioner’s
`
`inter partes challenge to U.S. Patent Nos. 9,211,253; 9,468,747; and 9,629,965.
`
`These proceedings have been designated Case Nos. IPR2019-00685, IPR2019-
`
`00688, and IPR2019-00694, respectively. I have not applied to appear pro hac
`
`vice in other proceedings before the Office in the last three (3) years.
`
`10.
`
`I am familiar with the subject matter at issue in the present
`
`proceeding. This familiarity comes from having:
`
`a.
`
`Reviewed in detail the pleadings submitted by Petitioner in this Case
`
`Nos. IPR2019-00685, IPR2019-00688, and IPR2019-00694;
`
`b.
`
`Reviewed in detail the challenged patents, U.S. Patent Nos.
`
`9,211,253; 9,468,747; and 9,629,965;
`
`c.
`
`Reviewed in detail exhibits relied upon by Petitioner, such as Exhibit
`
`1002 (Declaration of Maureen Donovan, Ph.D.) and Exhibit 1003 (Declaration of
`
`Günther Hochhaus, Ph.D.), etc.;
`
`d.
`
`Engaged in extensive strategic and substantive discussions regarding
`
`this proceeding with Jessamyn S. Berniker, who is the lead counsel for Patent
`
`Owner Adapt Pharma Operations Limited in this case;
`
`e.
`
`Engaged in the representation of Patent Owner Adapt Pharma
`
`Operations Limited in related matters in federal district courts, including the
`
`assertion of U.S. Patent Nos. 9,211,253; 9,468,747; and 9,629,965 in Adapt
`
`Opiant Exhibit 2038
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00694
`Page 3
`
`
`
`Pharma Operations Ltd., et al. v. Teva Pharmaceuticals USA, Inc., et al., Case No.
`
`2:16-cv-07721-BRM-JAD (D.N.J.) (consolidated) and Adapt Pharma Operations
`
`Ltd., et al. v. Perrigo UK FINCO Limited Partnership, Case No. 2:18-cv-15287-
`
`BRM-JAD (D.N.J.).
`
`11.
`
`I have reviewed in detail relevant case law and other legal authority
`
`related to the allegations made in the Petition.
`
`*
`
`*
`
`*
`
`I hereby declare that all statements made herein of my own knowledge are
`
`true and that all statements made on information and belief are believed to be true,
`
`and further that these statements were made with the knowledge that willful false
`
`statements and the like are punishable by fine or imprisonment, or both, under
`
`Section 1001 of Title 18, United States Code and may jeopardize the validity of
`
`any application or any patent issuing thereon.
`
`/Ana C. Reyes/
`Ana C. Reyes
`
`Opiant Exhibit 2038
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00694
`Page 4
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
